Market Place
Sourcing Support
Matinas BioPharma Terminates MAT2203 Partnership, Cuts Workforce
31 Oct 2024 //
GLOBENEWSWIRE
Matinas BioPharma Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
Matinas BioPharma To Host Q2 2024 Results Call On August 14
07 Aug 2024 //
GLOBENEWSWIRE
Matinas BioPharma Treats Limb-Threatening Mucor Infection with Oral MAT2203
24 Jun 2024 //
GLOBENEWSWIRE
Matinas BioPharma`s MAT2203 Featured In A.G.P. Fireside Chat
13 Jun 2024 //
GLOBENEWSWIRE
New Matinas Data Shows LNC Oligonucleotide Delivery
16 May 2024 //
GLOBENEWSWIRE
Matinas BioPharma Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Matinas LNC Platform For Oligonucleotide Delivery Featured At ASGCT
07 May 2024 //
GLOBENEWSWIRE
Matinas Q1 2024 Call, Business Update On May 9
02 May 2024 //
GLOBENEWSWIRE
Matinas BioPharma MAT2203 In Vivo Pulmonary Mucormycosis Efficacy Published
30 Apr 2024 //
GLOBENEWSWIRE
Matinas BioPharma Prices $10 Million Registered Direct Offering
03 Apr 2024 //
GLOBENEWSWIRE
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
27 Mar 2024 //
GLOBENEWSWIRE
Matinas Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel
25 Mar 2024 //
GLOBENEWSWIRE
Matinas Provides Positive Outcomes Update on MAT2203 Expanded Use Access Program
26 Feb 2024 //
GLOBENEWSWIRE
Matinas Reaches Agreement with FDA for Phase 3 Trial to Support NDA for MAT2203
20 Feb 2024 //
GLOBENEWSWIRE
Matinas BioPharma to Present at Biotech Showcase 2024
03 Jan 2024 //
GLOBENEWSWIRE
Matinas Showes in vivo Biological Activity in Two Inflammatory Disease Models
27 Dec 2023 //
GLOBENEWSWIRE
Matinas BioPharma Provides Update to MAT2203 Regulatory Pathway
21 Dec 2023 //
GLOBENEWSWIRE
Matinas Bio Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel
07 Nov 2023 //
GLOBENEWSWIRE
Matinas to Webcast Conference to Discuss Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Matinas BioPharma™s MAT2203 Expanded Program Achieves Clinical Resolution
11 Oct 2023 //
GLOBENEWSWIRE
Matinas BioPharma to Present at Two Investment Conferences in October 2023
28 Sep 2023 //
GLOBENEWSWIRE
Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
27 Sep 2023 //
GLOBENEWSWIRE
Matinas Announces Notification of NYSE American Continued Listing Deficiency
22 Sep 2023 //
GLOBENEWSWIRE
Matinas Bio to Participate in the H.C. Wainwright Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Matinas Announces Publication of Results from Phase 2 EnACT Trial of MAT2203
22 Aug 2023 //
GLOBENEWSWIRE
Matinas BioPharma Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Matinas Bio to Participate in the BTIG Virtual Biotechnology Conference 2023
02 Aug 2023 //
GLOBENEWSWIRE
Matinas to Webcast Conference Call to Discuss Q2 2023 Financial Results
26 Jul 2023 //
GLOBENEWSWIRE
BioNTech and Matinas end oral mRNA delivery collaboration
12 May 2023 //
ENDPTS
Matinas to Present at JMP Securities Life Sciences Conference on May 15, 2023
11 May 2023 //
GLOBENEWSWIRE
Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update
15 Mar 2023 //
GLOBENEWSWIRE
Matinas to Webcast Conference Call to Discuss 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
Matinas Announces that MAT2203 Will Be Featured in Presentations at ECCMID
02 Mar 2023 //
GLOBENEWSWIRE
Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
30 Jan 2023 //
GLOBENEWSWIRE
Matinas BioPharma to Provide Corporate Update on January 30, 2023
23 Jan 2023 //
GLOBENEWSWIRE
Matinas Announces Collaboration with National Resilience for LNC Platform
12 Jan 2023 //
GLOBENEWSWIRE
Matinas BioPharma Reports Third Quarter 2022 Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
Matinas to Webcast Conference Discussing Third Quarter 2022 Financial Results
27 Oct 2022 //
GLOBENEWSWIRE
Matinas climbs on mid-stage data for meningitis treatment
22 Oct 2022 //
GLOBENEWSWIRE
Matinas Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203
21 Oct 2022 //
GLOBENEWSWIRE
Matinas Announces IDSA has Selected the EnACT PII Trial of MAT2203
19 Oct 2022 //
GLOBENEWSWIRE
Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data
12 Oct 2022 //
GLOBENEWSWIRE
Matinas BioPharma to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Matinas BioPharma Reports Q2 2022 Rusult and Highlights Recent Progress
11 Aug 2022 //
GLOBENEWSWIRE
Matinas BioPharma to Participate in the BTIG Biotechnology Conference
01 Aug 2022 //
GLOBENEWSWIRE
Matinas Bio to Webcast Conference Call on Second Quarter 2022 Financial Results
28 Jul 2022 //
GLOBENEWSWIRE
Matinas BioPharma Announces Positive Opinion by EMA on ODD for MAT2203
25 Jul 2022 //
GLOBENEWSWIRE
Matinas BioPharma to Present at the LD Micro Invitational XII Conference
31 May 2022 //
GLOBENEWSWIRE
Matinas BioPharma Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Matinas BioPharma to Webcast Q1 2022 Financial and Operational Results
05 May 2022 //
GLOBENEWSWIRE
Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
03 May 2022 //
GLOBENEWSWIRE
BioNTech, Matinas BioPharma Enter Research Collaboration for mRNA-based Vaccines
11 Apr 2022 //
GLOBENEWSWIRE
Matinas BioPharma to Present at the Needham Virtual Healthcare Conference
06 Apr 2022 //
GLOBENEWSWIRE
Matinas BioPharma Reports Q4 and FY 2021 Financial Results
08 Mar 2022 //
GLOBENEWSWIRE
Matinas BioPharma to release Q4 and Full Year 2021 Financial Results
28 Feb 2022 //
GLOBENEWSWIRE
Matinas BioPharma Announces Unanimous DSMB Approval
16 Dec 2021 //
GLOBENEWSWIRE
Matinas Initiates Dosing in Ph1 Study of Potential First Oral Aminoglycoside
21 Oct 2021 //
GLOBENEWSWIRE
Matinas, Dynavax top weekly healthcare gainers; InnovAge, BeyondSpring trail
24 Sep 2021 //
SEEKINGALPHA
Matinas BioPharma Announces K. Penkus Corzo as Nominee to the Board of Directors
20 Sep 2021 //
GLOBENEWSWIRE
